Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects.
The epithelial sodium channel (ENaC) is a principal site for sodium reabsorption and as such may participate importantly in blood pressure (BP) regulation. Amiloride, a direct inhibitor of ENaC, characteristically has mild antihypertensive properties, consistent with ENaC having more minor influences on BP regulation. Counter-regulatory influences may, however, prevent amiloride from effectively lowering BP. Aldosterone secretion is known to increase in response to the reduced sodium reabsorption that follows amiloride inhibition of ENaC, and because aldosterone upregulates ENaC function, we considered the possibility that secondary hyperaldosteronism mitigates the ability of amiloride to reduce BP. In the present study, the BP responses to amiloride (5 mg per day), spironolactone (25 mg per day), the combination of the 2 drugs, and placebo were studied in healthy normotensive subjects. Over 4 weeks of treatment, the combination of amiloride and spironolactone lowered systolic BP by 4.6+/-1.6 (mean+/-SEM) mm Hg (P=0.022) and diastolic BP by 2.2+/-1.2 mm Hg (P=0.30), whereas either drug alone had no significant effect on BP. The findings suggest that the 2 drugs with different modes of action-amiloride, a direct inhibitor of ENaC, and spironolactone, a mineralocorticoid receptor antagonist-may compliment each other's ability to inhibit ENaC and thereby reduce sodium reabsorption to a point at which BP decreases. On the other hand, we cannot rule out that the BP response resulted from the greater dose of total drug. The lowering of BP with small doses of inhibitors of ENaC serves as additional evidence for the importance of ENaC to the tonic maintenance of BP.
Pratt
J H
JH
Department of Medicine, Indiana University School of Medicine, VA Medical Center, Indianapolis, Indiana, USA. johpratt@iupui.edu
Eckert
G J
GJ
Newman
S
S
Ambrosius
W T
WT
D000328:Adult; D000584:Amiloride / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D004357:Drug Synergism; D053503:Epithelial Sodium Channels; D005260:Female; D006801:Humans; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D026941:Sodium Channel Blockers; D015222:Sodium Channels; D013148:Spironolactone / Q000008:administration & dosage / Q000494:pharmacology*
D053503:Epithelial Sodium Channels; D000451:Mineralocorticoid Receptor Antagonists; D026941:Sodium Channel Blockers; D015222:Sodium Channels; D013148:Spironolactone; D000584:Amiloride